Genetics of hypertrophic cardiomyopathy: Advances and pitfalls in molecular diagnosis and therapy

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 195-208

  Roma Rodrigues, Catarina ^a   Fernandes, Alexandra R ^a,b  

^a Faculty of Pharmacy of the University of Porto   (Portugal)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Hypertrophic cardiomyopathy; Molecular diagnosis; Next generation sequencing; Sarcomere; Sudden cardiac death

Indexed keywords

CAUSAL ATTRIBUTION; DNA MICROARRAY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NANOTECHNOLOGY; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; REGENERATIVE MEDICINE; REVIEW; SANGER SEQUENCING; SEQUENCE ANALYSIS; TISSUE ENGINEERING;

EID: 84907526364     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S49126     Document Type: Review

References (108)

1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816.
2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–276.
3. Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J. 2004;25:1772–1775.
4. Khouzam RN, Naidu SS. Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep. 2014;16:478.
5. Efthimiadis GK, Pagourelias ED, Gossios T, Zegkos T. Hypertrophic cardiomyopathy in 2013: current speculations and future perspectives. World J Cardiol. 2014;6:26–37.
6. Santos S, Freitas AT, Fernandes AR. Overview of HCM genomics and transcriptomics: molecular tools in HCM assessment for application in clinical medicine. Cardiovascular Disease II. iConcept Press. Available from: http://www.iconceptpress.com/books/cardiovascular-disease-ii/. In press 2014.
7. Poggesi C, Ho CY. Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation? J Muscle Res Cell Motil. 2014;35: 37–45.
8. Enriquez AD, Goldman ME. Management of hypertrophic cardiomyopathy. Ann Glob Health. 2014;80:35–45.
9. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201–211.
10. Wilcken DEL. Physiology of the normal heart. Medicine. 2010;38: 336–339.
11. Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15:158–170.
12. Layland J, Shah AM. Biochemistry and physiology of cardiac muscle. Medicine. 2006;34:169–172.
13. Solaro RJ. Sarcomere control mechanisms and the dynamics of the cardiac cycle. J Biomed Biotechnol. 2010;2010:105648.
14. Guclu A, Germans T, Witjas-Paalberends ER, et al. ENerGetIcs in hypertrophic cardiomyopathy: translation between MRI, PET and cardiac myofilament function (ENGINE study). Neth Heart J. 2013;21:567–571.
15. Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014;106: 1236–1249.
16. Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–563.
17. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005;65:40–51.
18. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348: 2007–2018.
19. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013; 381:242–255.
20. Ho CY. Hypertrophic cardiomyopathy: preclinical and early phenotype. J Cardiovasc Transl Res. 2009;2:462–470.
21. Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113:1550–1555.
22. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy: the search for obstruction. Circulation. 2006;114:2200–2202.
23. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:e153–e203.
24. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705–715.
25. Jacoby DL, DePasquale EC, McKenna WJ. Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ. 2013;185:127–134.
26. Sankaranarayanan R, Fleming EJ, Garratt CJ. Mimics of hypertrophic cardiomyopathy – diagnostic clues to aid early identification of phenocopies. Arrhythmia and Electrophysiology Review. 2013;2:36–40.
27. Semsarian C, Ingles J. Expanding the genetic spectrum of hypertrophic cardiomyopathy: X marks the spot. Circ Cardiovasc Genet. 2013;6:528–530.
28. Hartmannova H, Kubanek M, Sramko M, et al. Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene. Circ Cardiovasc Genet. 2013;6:543–551.
29. Kuster DW, Sadayappan S. MYBPC3’s alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation. Pflugers Arch. 2014;466:207–213.
30. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:449–457.
31. Rowin EJ, Maron MS. The ever expanding spectrum of phenotypic diversity in hypertrophic cardiomyopathy. Am J Cardiol. 2013;112: 463–464.
32. Dhandapany PS, Sadayappan S, Xue Y, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet. 2009;41:187–191.
33. Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848–1853.
34. Andersen PS, Havndrup O, Bundgaard H, et al. Genetic and phenotypic characterization of mutations in myosin-binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency. Eur J Hum Genet. 2004;12:673–677.
35. Jääskeläinen P, Miettinen R, Kärkkäinen P, Toivonen L, Laakso M, Kuusisto J. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med. 2004;36:23–32.
36. Waldmüller S, Sakthivel S, Saadi AV, et al. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2003;35:623–636.
37. Brito D, Miltenberger-Miltenyi G, Vale Pereira S, Silva D, Diogo AN, Madeira H. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol. 2012;31:577–587.
38. Solomon SD, Jarcho JA, McKenna W, et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990;86:993–999.
39. Ko YL, Lien WP, Chen JJ, Wu CW, Tang TK, Liew CC. No evidence for linkage of familial hypertrophic cardiomyopathy and chromosome 14q1 locus D14S26 in a Chinese family: evidence for genetic heterogeneity. Hum Genet. 1992;89:597–601.
40. Dausse E, Schwartz K. Genetic heterogeneity of familial hypertrophic cardiomyopathy. Neuromuscul Disord. 1993;3:483–486.
41. Gajendrarao P, Krishnamoorthy N, Kassem HS, et al. Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One. 2013;8:e59206.
42. Bos JM, Ackerman MJ. Z-disc genes in hypertrophic cardiomyopathy: stretching the cardiomyopathies? J Am Coll Cardiol. 2010;55: 1136–1138.
43. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058–1064.
44. Ho CY. Hypertrophic cardiomyopathy. Heart Fail Clin. 2010;6: 141–159.
45. Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002;105:446–451.
46. Santos S, Marques V, Pires M, et al. High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort. BMC Med Genet. 2012;13:17.
47. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042–2048.
48. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation. 2010;122:2441–2449.
49. Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation. 2010;122:2430–2440.
50. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline. J Card Fail. 2009;15:83–97.
51. van Langen IM, Arens Y, Baars H, et al; ICIN Working Group on Hereditary Heart Diseases. Genetic diagnostics and genetic counseling in hypertrophic cardiomyopathy (HCM). Neth Heart J. 2010;18:144–159.
52. Kapplinger JD, Landstrom AP, Bos JM, et al. Distinguishing hypertrophic cardiomyopathy-associated mutations from background genetic noise. J Cardiovasc Transl Res. 2014;7:347–361.
53. Dames S, Durtschi J, Geiersbach K, Stephens J, Voelkerding KV. Comparison of the Illumina genome analyzer and Roche 454 GS FLX for resequencing of hypertrophic cardiomyopathy-associated genes. J Biomol Tech. 2010;21:73–80.
54. Rizzo JM, Buck MJ. Key principles and clinical applications of “next-generation” DNA sequencing. Cancer Prev Res (Phila). 2012;5:887–900.
55. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest. 2010;40:360–369.
56. Santos S, Lança V, Oliveira H, et al. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting. Rev Port Cardiol. 2011;30:7–18.
57. Hert DG, Fredlake CP, Barron AE. Advantages and limitations of next-generation sequencing technologies: a comparison of electrophoresis and non-electrophoresis methods. Electrophoresis. 2008;29:4618–4626.
58. Mardis ER. A decade’s perspective on DNA sequencing technology. Nature. 2011;470:198–203.
59. Li Z, Huang J, Zhao J, et al. Rapid molecular genetic diagnosis of hypertrophic cardiomyopathy by semiconductor sequencing. J Transl Med. 2014;12:173.
60. Mook ORF, Haagmans MA, Soucy JF, et al. Targeted sequence capture and GS-FLX titanium sequencing of 23 hypertrophic and dilated cardiomyopathy genes: implementation into diagnostics. J Med Genet. 2013;50:614–626.
61. Millat G, Chanavat V, Crehalet H, Rousson R. Development of a high resolution melting method for the detection of genetic variations in hypertrophic cardiomyopathy. Clin Chim Acta. 2010;411:1983–1991.
62. Fokstuen S, Makrythanasis P, Nikolaev S, et al. Multiplex targeted high-throughput sequencing for Mendelian cardiac disorders. Clin Genet. 2014;85:365–370.
63. Waldmuller S, Freund P, Mauch S, Toder R, Vosberg HP. Low-density DNA microarrays are versatile tools to screen for known mutations in hypertrophic cardiomyopathy. Hum Mutat. 2002;19:560–569.
64. Fokstuen S, Lyle R, Munoz A, et al. DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat. 2008;29:879–885.
65. Brion M, Allegue C, Monserrat L, et al. Large scale analysis of HCM mutations in sudden cardiac death. Forensic Sci Int. 2008;1:549–550.
66. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31:2715–2726.
67. Millat G, Bouvagnet P, Chevalier P, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53:261–267.
68. Zeller R, Ivandic BT, Ehlermann P, et al. Large-scale mutation screening in patients with dilated or hypertrophic cardiomyopathy: a pilot study using DGGE. J Mol Med (Berl). 2006;84:682–691.
69. Ehlermann P, Weichenhan D, Zehelein J, et al. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet. 2008;9:95.
70. Rodríguez-García MI, Monserrat L, Ortiz M, et al. Screening mutations in myosin binding protein C3 gene in a cohort of patients with hypertrophic cardiomyopathy. BMC Med Genet. 2010;11:67.
71. Annapurna SD, Reena TR, Nallari P, Calambur N. Genetic variation in exon 5 of troponin-I gene in hypertrophic cardiomyopathy cases. Indian J Hum Genet. 2007;13:50–53.
72. van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003;108:445–451.
73. van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:1903–1910.
74. Erali M, Wittwer CT. High resolution melting analysis for gene scanning. Methods. 2010;50:250–261.
75. Brion M, Allegue C, Gil R, et al. Identification of a novel MYBPC3 gene variant in a patient with hypertrophic cardiomyopathy. Ann Clin Lab Sci. 2010;40:285–289.
76. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15:733–747.
77. Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour. 2011;11:759–769.
78. Wang H, Nettleton D, Ying K. Copy number variation detection using next generation sequencing read counts. BMC Bioinformatics. 2014;15:109.
79. Boonpeng H, Yusoff K. The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): rationale, potential and challenges. Mol Cytogenet. 2013;6:8.
80. Voelkerding KV, Dames S, Durtschi JD. Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2010;12:539–551.
81. Ellims AH, IIes LM, Ling LH, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging. May 12, 2014. [Epub ahead of print].
82. Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. 2013;50:228–239.
83. Wang Y, Wang Z, Yang Q, et al. Autosomal recessive transmission of MYBPC3 mutation results in malignant phenotype of hypertrophic cardiomyopathy. PLoS One. 2013;8:e67087.
84. Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet. 2011;4:110–122.
85. Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA. A new era in clinical genetic testing for hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:381–391.
86. Millat G, Chanavat V, Rousson R. Evaluation of a new NGS method based on a custom AmpliSeq library and ion torrent PGM sequencing for the fast detection of genetic variations in cardiomyopathies. Clin Chim Acta. 2014;433C:266–271.
87. Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet. 2012;91:513–519.
88. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619–628.
89. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation. 2011;123:1021–1037.
90. Mestroni L, Taylor MR. Hearing the noise the challenges of human genome variation in genetic testing. J Am Coll Cardiol. 2011;57: 2328–2329.
91. The 1000 Genomes Project Consortium. A map of human genome variation from populations – scale sequencing. Nature. 2010;467:1061–1073.
92. Watkins H. Assigning a causal role to genetic variants in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6:2–4.
93. Das K J, Ingles J, Bagnall RD, Semsarian C. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med. 2014;16:286–293.
94. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002;87: 169–176.
95. Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014;64:1–10.
96. Efthimiadis GK, Pitsis A, Pagourelias ED, et al. Surgical septal myectomy for hypertrophic cardiomyopathy in Greece: a single-center initial experience. Hellenic J Cardiol. 2014;55:132–138.
97. Moretti A, Laugwitz KL, Dorn T, Sinnecker D, Mummery C. Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med. 2013;3:a014027.
98. Garbern JC, Mummery C., Lee RT. Model systems for cardiovascular regenerative biology. Cold Spring Harb Perspect Med. 2013;3:a014019.
99. Vunjak Novakovic G, Eschenhagen T, Mummery C. Myocardial tissue engineering: in vitro models. Cold Spring Harb Perspect Med. 2014;4:a014076.
100. Liang P, Du J. Human induced pluripotent stem cell for modeling cardiovascular diseases. Regenerative Medicine Research. 2014;2:4.
101. Yi BA, Mummery C., Chien KR. Direct cardiomyocyte reprogramming: a new direction for cardiovascular regenerative medicine. Cold Spring Harb Perspect Med. 2013;3:a014050.
102. Kumar N, Kumar R. Nanomedicine for treatment of cardiovascular diseases. In: Nanotechnology and Nanomaterials in the Treatment of Life-threatening Diseases. Waltham, MA, USA: Elsevier; 2014.
103. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211–1217.
104. Bahrudin U, Mizuta E, Ariani MD, Nindita Y, Hisatome I. Sensitivity and specificity of denaturing HPLC to detect MYBPC3 gene mutations in hypertrophic cardiomyopathy. Yonago Acta Med. 2009;52:121–125.
105. Bos JM, Poley RN, Ny M, et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab. 2006;88:78–85.
106. van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:602–610.
107. Chen D, Wang YY, Chuai ZR, et al. High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep. 2014;4:4168.
108. Allegue C, Gil R, Blanco-Verea A, et al. Prevalence of HCM and long QT syndrome mutations in young sudden cardiac death-related cases. Int J Legal Med. 2011;125:565–572.